Markman M, Cleary S, King M E, Howell S B
Med Pediatr Oncol. 1985;13(4):191-3. doi: 10.1002/mpo.2950130406.
Eight patients with histologically-documented malignant pleural effusions received a total of ten courses of intrapleurally administered chemotherapy with cisplatin (100 mg/m2) and cytarabine (10(-2) M). Sodium thiosulfate was simultaneously administered intravenously to protect against cisplatin-induced nephrotoxicity. There was no local toxicity observed and the only significant systemic toxicity (bone marrow depression) developed in a patient with poor marrow reserve prior to the initiation of therapy. Six of seven evaluable patients exhibited major reductions (greater than 75%) in the size of their effusions lasting for 2 to 10 plus months (median: 4 months). We conclude that the intrapleural administration of this chemotherapy regimen results in objective and subjective improvement in patients with malignant pleural effusions with minimal local and systemic toxicity (except for cisplatin-induced emesis) and does not require chest tube drainage or prolonged hospitalization.
8例经组织学证实的恶性胸腔积液患者共接受了10个疗程的胸膜腔内化疗，化疗药物为顺铂（100mg/m²）和阿糖胞苷（10⁻²M）。同时静脉注射硫代硫酸钠以预防顺铂引起的肾毒性。未观察到局部毒性，唯一显著的全身毒性（骨髓抑制）出现在治疗开始前骨髓储备较差的1例患者中。7例可评估患者中有6例胸腔积液大小显著缩小（超过75%），持续2至10多个月（中位数：4个月）。我们得出结论，胸膜腔内给予这种化疗方案可使恶性胸腔积液患者在客观和主观上得到改善，局部和全身毒性最小（顺铂引起的呕吐除外），且无需胸腔闭式引流或长期住院。
